Bliss GVS Pharma Announces Voting Results for Director Appointments
Bliss GVS Pharma Limited has announced the results of a postal ballot concerning two special resolutions for director appointments. Mr. Vijayanarayanan Mahadevan and Mr. Deepak Rameschandra Shah were appointed as Non-Executive and Independent Directors for five-year terms. Both resolutions passed with overwhelming support via postal ballot.
The appointment of new directors can have a medium-term impact on the company's strategic direction and governance.
The announcement reports the successful passing of special resolutions for the appointment of two independent directors, indicating positive corporate governance and board strengthening.
Bliss GVS Pharma Limited has announced the voting results of a postal ballot conducted via remote e-voting. The company sought approval from its members for two special resolutions regarding the appointment of directors.
Mr. Vijay Yadav, Partner at AVS & Associates, served as the Scrutinizer for the postal ballot and e-voting process. His report was submitted to the company on May 11, 2026.
The voting results, along with the Scrutinizer's Report, were enclosed and submitted in compliance with Section 108 and 110 of the Companies Act, 2013, and Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The information is also available on the company's website, www.blissgvs.com.
The first special resolution concerned the appointment of Mr. Vijayanarayanan Mahadevan (DIN: 06639177) as a Non-Executive and Independent Director for a term of five years. The voting on this resolution saw 100.0000% of the votes polled in favour, with 0 votes against, based on postal ballot.
The second special resolution was for the appointment of Mr. Deepak Rameschandra Shah (DIN: 06954206) as a Non-Executive and Independent Director for a term of five years. This resolution also passed with a significant majority, with 99.9948% of votes in favour through postal ballot and 0.0052% against.
What to do with a filing like this
Bliss GVS Pharma Limited filed this with the NSE as a statutory disclosure, categorised under shareholder meetings. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Bliss GVS Pharma Limited. Read the original for the full detail.